SCHEMBL1067247

SCHEMBL1067247

CCOC(=O)C=C(C)Oc1ccc(OC)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
HDAC3 O15379 2/20 0.43
HDAC4 P56524 2/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC7 Q8WUI4 2/20 0.43
HDAC2 Q92769 2/20 0.43
HDAC10 Q969S8 2/20 0.43
HDAC11 Q96DB2 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
HDAC9 Q9UKV0 2/20 0.43
HDAC5 Q9UQL6 2/20 0.43
GLA P06280 1/20 0.43
GAA P10253 4/20 0.43
LMNA P02545 2/20 0.43
CYP3A4 P08684 3/20 0.42
HPGD P15428 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1067245 1.00 KMT2A (0.43) KMT2AHDAC3HDAC4HDAC1HDAC7
SCHEMBL1069140 0.85 MAPT (0.48) KMT2ALMNAHPGDL3MBTL1TDP1
SCHEMBL1069136 0.85 MAPT (0.48) KMT2ALMNAHPGDL3MBTL1TDP1
SCHEMBL1069139 0.85 MAPT (0.48) KMT2ALMNAHPGDL3MBTL1TDP1
SCHEMBL1064148 0.85 ALDH1A1 (0.48) LMNACYP3A4HPGDL3MBTL1TDP1
SCHEMBL1067349 0.85 ALDH1A1 (0.48) LMNACYP3A4HPGDL3MBTL1TDP1
SCHEMBL1064150 0.85 ALDH1A1 (0.48) LMNACYP3A4HPGDL3MBTL1TDP1
SCHEMBL19167210 0.83 ALDH1A1 (0.47) KMT2AGLACYP3A4HPGDPOLB
SCHEMBL2207899 0.81 HDAC3 (0.50) KMT2AHDAC3HDAC4HDAC1HDAC7
SCHEMBL30039541 0.81 HDAC3 (0.50) KMT2AHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 KMT2A 2072/4885HDAC3 2065/4885HDAC4 2182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.